[1]
World Health Organization. Global tuberculosis report. Geneva:
WHO. 2016.
[2]
Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163(9): 1009-21.
[3]
Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340(5): 367-73.
[4]
Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367(9514): 926-37.
[5]
Forty-fourth World Health Assembly WHA44/1991/REC/1.
Geneva: WHO 1991.
[6]
An expanded DOTS framework for effective tuberculosis control.
Geneva: WHO 2002.
[7]
Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002; 359(9308): 775-80.
[8]
Raviglione MC, Uplekar MW. WHO’s new Stop TB Strategy. Lancet 2006; 367(9514): 952-5.
[9]
Maher D, Dye C, Floyd K, et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007; 85(5): 341-7.
[10]
The Stop TB Strategy: Building on and Enhancing DOTS to Meet
the TB-Related Millennium Development Goals
WHO/HTM/TB2006368. Geneva: WHO. 2006.
[11]
Stop TB Partnership The Global Plan to Stop TB 2006-2015
WHO/HTM/STB/200635. Geneva: WHO. 2006.
[12]
Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367(9514): 938-40.
[13]
Un.org. Retrieved 11 October 2016, from United Nations..
[14]
Deffur A, Mulder NJ, Wilkinson RJ. Co-infection with Mycobacterium tuberculosis and human immunodeficiency virus: an overview and motivation for systems approaches. Pathog Dis 2013; 69(2): 101-13.
[15]
Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326(4): 231-5.
[16]
Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320(9): 545-50.
[17]
Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6(4): e17601.
[18]
Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19: 1-63.
[19]
Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358(9294): 1687-93.
[20]
Lee SS, Meintjes G, Kamarulzaman A, Leung CC. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. Respirology 2013; 18(6): 912-22.
[21]
Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005; 5(10): 819-26.
[22]
A guide to monitoring and evaluation for collaborative TB/HIV activities. Geneva: WHO 2009.
[23]
Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119(2): 183-201.
[24]
Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13(4): 501-7.
[25]
Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14(Suppl. 3): S47-56.
[26]
Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50(Suppl. 3): S201-7.
[27]
Nunes EA, De Capitani EM, Coelho E, et al. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003. Int J Tuberc Lung Dis 2005; 9(5): 494-500.
[28]
Tuberculosis morbidity--United States, 1996. JAMA 1997; 278(16): 1309.
[29]
Cantwell MF, Binkin NJ. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tuber Lung Dis 1996; 77(3): 220-5.
[30]
Wilkinson D, Davies GR. The increasing burden of tuberculosis in rural South Africa--impact of the HIV epidemic. S Afr Med J 1997; 87(4): 447-50.
[31]
Churchyard GJ, Kleinschmidt I, Corbett EL, Mulder D, De Cock KM. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis 1999; 3(9): 791-8.
[32]
Seeling S, Mavhunga F, Thomas A, Adelberger B, Ulrichs T. Barriers to access to antiretroviral treatment for HIV-positive tuberculosis patients in Windhoek, Namibia. Int J Mycobacteriol 2014; 3(4): 268-75.
[33]
HIV testing and treatment among tuberculosis patients --- Kenya, 2006-2009. MMWR Morb Mortal Wkly Rep 2010; 59(46): 1514-7.
[34]
Prado TN, Rajan JV, Miranda AE, et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: a hierarchical polytomous analysis. Braz J Infect Dis 2017; 21(2): 162-70.
[35]
Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One 2013; 8(5): e64915.
[36]
Manjareeka M, Nanda S. Prevalence of HIV infection among tuberculosis patients in Eastern India. J Infect Public Health 2013; 6(5): 358-62.
[37]
Trinh QM, Nguyen HL, Do TN, et al. Tuberculosis and HIV co-infection in Vietnam. Int J Infect Dis 2016; 46: 56-60.
[38]
Gao L, Zhou F, Li X, Jin Q. HIV/TB co-infection in mainland China: a meta-analysis. PLoS One 2010; 5(5): e10736.
[39]
Brighenti S, Andersson J. Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection. Biochem Biophys Res Commun 2010; 396(1): 50-7.
[40]
Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191(2): 150-8.
[41]
MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94(10): 5243-8.
[42]
Walker L, Lowrie DB. Killing of Mycobacterium microti by immunologically activated macrophages. Nature 1981; 293(5827): 69-71.
[43]
MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003; 302(5645): 654-9.
[44]
Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002; 70(8): 4501-9.
[45]
Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010; 8(4): 296-307.
[46]
Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013; 254(1): 54-64.
[47]
Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200(6): 761-70.
[48]
Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000; 192(1): 117-22.
[49]
Heyderman RS, Makunike R, Muza T, et al. Pleural tuberculosis in Harare, Zimbabwe: the relationship between human immunodeficiency virus, CD4 lymphocyte count, granuloma formation and disseminated disease. Trop Med Int Health 1998; 3(1): 14-20.
[50]
Di Perri G, Cazzadori A, Vento S, et al. Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients. Tuber Lung Dis 1996; 77(3): 244-9.
[51]
Chen CY, Huang D, Wang RC, et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog 2009; 5(4): e1000392.
[52]
Hess C, Altfeld M, Thomas SY, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004; 363(9412): 863-6.
[53]
Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev 2013; 254(1): 78-101.
[54]
Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009; 180(12): 1262-70.
[55]
Patel NR, Zhu J, Tachado SD, et al. HIV impairs TNF-alpha mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 2007; 179(10): 6973-80.
[56]
Patel NR, Swan K, Li X, Tachado SD, Koziel H. Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. J Leukoc Biol 2009; 86(1): 53-60.
[57]
Gupta RK, Lawn SD, Bekker LG, Caldwell J, Kaplan R, Wood R. Impact of human immunodeficiency virus and CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J Tuberc Lung Dis 2013; 17(8): 1014-22.
[58]
Bezuidenhout J, Roberts T, Muller L, van Helden P, Walzl G. Pleural tuberculosis in patients with early HIV infection is associated with increased TNF-alpha expression and necrosis in granulomas. PLoS One 2009; 4(1): e4228.
[59]
Ansari AW, Kamarulzaman A, Schmidt RE. Multifaceted Impact of Host C-C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection. Front Immunol 2013; 4: 312.
[60]
Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324(23): 1644-50.
[61]
Lee MP, Chan JW, Ng KK, Li PC. Clinical manifestations of tuberculosis in HIV-infected patients. Respirology 2000; 5(4): 423-6.
[62]
WHO. The global plan to stop TB 2011-2015. Geneva,. 2011.
[63]
Greenberg SD, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology 1994; 193(1): 115-9.
[64]
Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10(5): 388-98.
[65]
Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148(5): 1292-7.
[66]
Perlman DC, el-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997; 25(2): 242-6.
[67]
Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136(3): 570-4.
[68]
Swaminathan S, Padmapriyadarsini C, Narendran G. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010; 50(10): 1377-86.
[69]
Archibald LK, McDonald LC, Nwanyanwu O, et al. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Infect Dis 2000; 181(4): 1414-20.
[70]
Crump JA, Ramadhani HO, Morrissey AB, et al. Bacteremic disseminated tuberculosis in sub-saharan Africa: a prospective cohort study. Clin Infect Dis 2012; 55(2): 242-50.
[71]
Reddy EA, Shaw AV, Crump JA. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(6): 417-32.
[72]
Ssali FN, Kamya MR, Wabwire-Mangen F, et al. A prospective study of community-acquired bloodstream infections among febrile adults admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19(5): 484-9.
[73]
Chan ED, Heifets L, Iseman MD. Immunologic diagnosis of tuberculosis: a review. Tuber Lung Dis 2000; 80(3): 131-40.
[74]
Chaudhary M, Gupta S, Khare S, Lal S. Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. Indian J Med Microbiol 2010; 28(4): 281-9.
[75]
Cantwell MF, Snider DE Jr, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272(7): 535-9.
[76]
Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec 2006; 81(42): 408.
[77]
Addressing the threat of tuberculosis caused by extensively drug-resistant Mycobacterium tuberculosis. Wkly Epidemiol Rec 2006; 81(41): 386-90.
[78]
Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117(3): 744-51.
[79]
Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13(6): 529-39.
[80]
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD
Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
Geneva: WHO. 1997.
[81]
WHO treatment guidelines for drug-resistant tuberculosis, 2016
update WHO guidelines approved by the guidelines review
committee. Geneva: WHO. 2016.
[82]
Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196(Suppl. 1): S86-S107.
[83]
Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009; 4(5): e5561.
[84]
From the Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. JAMA 1991; 266(11): 1483-5.
[85]
Outbreak of multidrug-resistant tuberculosis at a hospital--New
York City, 1991. MMWR Morb Mortal Wkly Rep 1993; 42(22):
427-, 433-434.
[86]
Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276(15): 1229-35.
[87]
Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326(23): 1514-21.
[88]
Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993; 168(4): 1052-5.
[89]
Moro ML, Gori A, Errante I, et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. AIDS 1998; 12(9): 1095-102.
[90]
Ritacco V, Di Lonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis 1997; 176(3): 637-42.
[91]
Valway SE, Greifinger RB, Papania M, et al. Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. J Infect Dis 1994; 170(1): 151-6.
[92]
Mac-Arthur A, Gloyd S, Perdigão P, Noya A, Sacarlal J, Kreiss J. Characteristics of drug resistance and HIV among tuberculosis patients in Mozambique. Int J Tuberc Lung Dis 2001; 5(10): 894-902.
[93]
Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328(16): 1137-44.
[94]
Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353(9167): 1843-7.
[95]
Lutfey M, Della-Latta P, Kapur V, et al. Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 1996; 153(2): 837-40.
[96]
March F, Garriga X, Rodríguez P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997; 25(5): 1044-7.
[97]
Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25(6): 1465-7.
[98]
Jenny-Avital ER. Acquired rifampin resistance in AIDS-related TB. AIDS Clin Care 2002; 14(8): 72-3.
[99]
Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med 1995; 332(5): 336-7.
[100]
Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA 2006; 103(18): 7042-7.
[101]
Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998; 19(6): 481-94.
[102]
Meemken L, Hanhoff N, Tseng A, Christensen S, Gillessen A. Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. Ann Pharmacother 2015; 49(7): 796-807.
[103]
Damle BD, Mummaneni V, Kaul S, Knupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002; 46(2): 385-91.
[104]
Mannheimer SB, Sepkowitz KA, Stoeckle M, Friedman CR, Hafner A, Riley LW. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City. Int J Tuberc Lung Dis 1997; 1(4): 319-25.
[105]
Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365(9456): 318-26.
[106]
Drobniewski F, Eltringham I, Graham C, Magee JG, Smith EG, Watt B. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002; 57(9): 810-6.
[107]
Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19(4): 399-406.
[108]
Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39(11): 1709-12.
[109]
Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22(5): 601-10.
[110]
Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R, Easterbrook PJ. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One 2012; 7(11): e40623.
[111]
Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57(2): 167-70.
[112]
Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8(8): 516-23.
[113]
Eshun-Wilson I, Havers F, Nachega JB, et al. Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Physicians AIDS Care (Chic) 2010; 9(2): 104-8.
[114]
Haddow LJ, Moosa MY, Easterbrook PJ. Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24(1): 103-8.
[115]
French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1(2): 107-15.
[116]
Jevtović DJ, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6(2): 140-3.
[117]
Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42(3): 418-27.
[118]
Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365(16): 1482-91.
[119]
Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercyto-kinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011; 37(5): 1248-59.
[120]
Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(4): 251-61.
[121]
Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis 2013; 56(3): 450-60.
[122]
Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20(2): F1-7.
[123]
Vignesh R, Kumarasamy N, Lim A, et al. TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2013; 64(3): 241-8.
[124]
Guidelines for intensified tuberculosis case-finding and isoniazid
preventive therapy for people living with HIV in resourceconstrained
settings. Geneva: WHO 2011.
[125]
Improving the Diagnosis and Treatment of Smear- Negative
Pulmonary and Extrapulmonary Tuberculosis among Adults and
Adolescents Recommendations for HIV-Prevalent and Resource-
Constrained Settings. Geneva: WHO 2007.
[126]
Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10(6): 663-9.
[127]
Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011; 134(6): 850-65.
[128]
Andrews JR, Lawn SD, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26(8): 987-95.
[129]
WHO policy on collaborative TB/HIV activities-guidelines for
national programmes and other stakeholders. Geneva: WHO 2012.
[130]
Automated real-time nucleic acid amplification technology for
rapid and simultaneous detection of tuberculosis and rifampi-cin
resistance: Xpert MTB/RIF system. Geneva: WHO 2011.
[131]
Strategic and Technical Advisory Group for Tuberculosis (STAGTB):
report of the tenth meeting. Geneva: World Health
Organization;. 2010.
[132]
Morris K. WHO recommends against inaccurate tuberculosis tests. Lancet 2011; 377(9760): 113-4.
[133]
Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183(3): 469-77.
[134]
Kashyap RS, Ramteke SS, Morey SH, Purohit HJ, Taori GM, Daginawala HF. Diagnostic value of early secreted antigenic target-6 for the diagnosis of tuberculous meningitis patients. Infection 2009; 37(6): 508-13.
[135]
Lawn SD, Gupta-Wright A. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications. Trans R Soc Trop Med Hyg 2016; 110(3): 180-5.
[136]
Gupta-Wright A, Peters JA, Flach C, Lawn SD. Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Med 2016; 14: 53.
[137]
The Use of Lateral Flow Urine Lipoarabinomannan Assay (LFLAM)
or the Diagnosis and Screening of Active Tuberculosis in
People Living with HIV: Policy. Geneva: WHO. 2015.
[138]
Cobelens FG, Egwaga SM, van Ginkel T, Muwinge H, Matee MI, Borgdorff MW. Tuberculin skin testing in patients with HIV infection: limited benefit of reduced cutoff values. Clin Infect Dis 2006; 43(5): 634-9.
[139]
Treatment of tuberculosis: Guidelines. Geneva: WHO. 2010.
[140]
Shankar EM, Vignesh R, Ellegård R, et al. HIV-Mycobacterium tuberculosis co-infection: a ‘danger-couple model’ of disease pathogenesis. Pathog Dis 2014; 70(2): 110-8.
[141]
Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol 2011; 2011: 103917.
[142]
Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167(4): 603-62.
[143]
Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006; 6(11): 710-25.
[144]
Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9(10): 1185-91.
[145]
Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154(4 Pt 1): 1034-8.
[146]
el-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26(5): 1148-58.
[147]
Pozniak AL, Coyne KM, Miller RF, et al. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med 2011; 12(9): 517-24.
[148]
Perriëns JH, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332(12): 779-84.
[149]
Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356(9240): 1470-4.
[150]
Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38(5): 731-6.
[151]
Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299(3): 849-57.
[152]
Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 1997; 107(1-2): 17-30.
[153]
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11): 1472-7.
Download PDF Flyer